ESLA
Price
$0.91
Change
-$0.04 (-4.21%)
Updated
Jul 25 closing price
Capitalization
32.91M
FATE
Price
$1.24
Change
-$0.01 (-0.80%)
Updated
Jul 25 closing price
Capitalization
142.14M
3 days until earnings call
Interact to see
Advertisement

ESLA vs FATE

Header iconESLA vs FATE Comparison
Open Charts ESLA vs FATEBanner chart's image
Estrella Immunopharma
Price$0.91
Change-$0.04 (-4.21%)
Volume$17.01K
Capitalization32.91M
Fate Therapeutics
Price$1.24
Change-$0.01 (-0.80%)
Volume$982.01K
Capitalization142.14M
ESLA vs FATE Comparison Chart in %
Loading...
ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ESLA vs. FATE commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ESLA is a Hold and FATE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ESLA: $0.91 vs. FATE: $1.24)
Brand notoriety: ESLA and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ESLA: 7% vs. FATE: 57%
Market capitalization -- ESLA: $32.91M vs. FATE: $142.14M
ESLA [@Biotechnology] is valued at $32.91M. FATE’s [@Biotechnology] market capitalization is $142.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ESLA’s FA Score shows that 0 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • ESLA’s FA Score: 0 green, 5 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, FATE is a better buy in the long-term than ESLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ESLA’s TA Score shows that 3 TA indicator(s) are bullish while FATE’s TA Score has 5 bullish TA indicator(s).

  • ESLA’s TA Score: 3 bullish, 6 bearish.
  • FATE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than ESLA.

Price Growth

ESLA (@Biotechnology) experienced а +6.66% price change this week, while FATE (@Biotechnology) price change was +9.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

ESLA is expected to report earnings on May 14, 2025.

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($142M) has a higher market cap than ESLA($32.9M). ESLA (-24.167) and FATE (-24.848) have similar YTD gains . ESLA has higher annual earnings (EBITDA): -8.82M vs. FATE (-168.28M). FATE has more cash in the bank: 240M vs. ESLA (421K). FATE has higher revenues than ESLA: FATE (13.3M) vs ESLA (0).
ESLAFATEESLA / FATE
Capitalization32.9M142M23%
EBITDA-8.82M-168.28M5%
Gain YTD-24.167-24.84897%
P/E RatioN/AN/A-
Revenue013.3M-
Total Cash421K240M0%
Total DebtN/A83.3M-
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ESLAFATE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
29%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
42%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
74%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
ESLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ETCIA0.01N/A
N/A
Electronic Tele-Communications, Inc.
INFT15.00N/A
N/A
Infinity Bancorp
JHIUF26.64N/A
N/A
James Hardie Industries plc
HKBNF0.40N/A
N/A
HKBN Ltd
TATYY29.38-0.43
-1.43%
Tate & Lyle, PLC

ESLA and

Correlation & Price change

A.I.dvisor tells us that ESLA and CARM have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESLA and CARM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ESLA
1D Price
Change %
ESLA100%
-4.16%
CARM - ESLA
25%
Poorly correlated
-1.62%
CYTOF - ESLA
23%
Poorly correlated
+4.54%
FATE - ESLA
23%
Poorly correlated
-0.80%
CMND - ESLA
23%
Poorly correlated
N/A
NRXS - ESLA
22%
Poorly correlated
+0.36%
More